Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis
Satveer K. Mahil, Martinsixtus Ezejimofor, L.S. Exton, et al.
British Journal of Dermatology (2020) Vol. 183, Iss. 4, pp. 638-649
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Psoriasis: a brief overview
Antony Raharja, Satveer K. Mahil, Juliet N. Barker
Clinical Medicine (2021) Vol. 21, Iss. 3, pp. 170-173
Open Access | Times Cited: 222
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 106
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*
Diamant Thaçi, Stefano Piaserico, Richard B. Warren, et al.
British Journal of Dermatology (2021) Vol. 185, Iss. 2, pp. 323-334
Open Access | Times Cited: 69
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 885-905
Open Access | Times Cited: 62
Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches
Marija V. Medovic, Vladimir Jakovljević, Vladimir Živković, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-17
Open Access | Times Cited: 52
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
Iain B. McInnes, L. Sawyer, Kristen Markus, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002074-e002074
Open Access | Times Cited: 48
Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseases
Alexander Schäbitz, Christina Hillig, Mohammad S. Mubarak, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents
Anastasia Drakos, Tiago Torres, Ronald Vender
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 111-111
Open Access | Times Cited: 10
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
Luca Mastorino, Paolo Dapavo, Sara Susca, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 22, Iss. 1, pp. 34-42
Open Access | Times Cited: 20
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
Kim Papp, Andrew Blauvelt, L. Puig, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 6, pp. 1149-1158
Open Access | Times Cited: 16
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 167-184
Open Access | Times Cited: 36
Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis
Eugenia Piragine, Davide Petri, Alma Martelli, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 6, pp. 1506-1506
Open Access | Times Cited: 25
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults
Wolf‐­Henning Boehncke, Nicolò Costantino Brembilla, Michael J. Nissen
Expert Review of Clinical Immunology (2020) Vol. 17, Iss. 1, pp. 5-13
Closed Access | Times Cited: 35
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
Kristen Sweet, Qingxuan Song, Matthew J. Loza, et al.
RMD Open (2021) Vol. 7, Iss. 2, pp. e001679-e001679
Open Access | Times Cited: 32
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy
Stefano Dastoli, Maria Passante, Francesco Loconsole, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 12
Innovative Approaches to Psoriasis: Small Molecules Targeting Key Signaling Pathways
Meeral Gosia, Gaurav Doshi, Siddhi Parab, et al.
Immunological Investigations (2025), pp. 1-37
Closed Access
Personalized prediction of psoriasis relapse post-biologic discontinuation: a machine learning-driven population cohort study
Shan Huang, Yanping Bai, Ruili Qi, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population
Mario Valenti, Giulia Pavia, Luigi Gargiulo, et al.
Journal of Dermatological Treatment (2021) Vol. 33, Iss. 3, pp. 1638-1642
Closed Access | Times Cited: 24
Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
Xinyan Zhang, Yu-Chun Cai, Xiaowen Hu, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 18
Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
Tomas Mickevičius, Andrew Pink, Maninder Bhogal, et al.
Cornea (2022) Vol. 42, Iss. 4, pp. 507-519
Open Access | Times Cited: 16
Identification of CD19 as a shared biomarker via PPARγ/β-catenin/Wnt3a pathway linking psoriasis and major depressive disorder
Bin Zhou, Ting Wu, Haitao Li, et al.
Journal of Affective Disorders (2024) Vol. 367, pp. 75-87
Closed Access | Times Cited: 3
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update
Catherine Smith, Z.Z.N. Yiu, Tracy Bale, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 2, pp. 270-272
Open Access | Times Cited: 6
Role of interleukins in dermatology: Exploring the immune mechanisms in skin diseases
Álvaro Prados‐Carmona, F.J. Navarro‐Triviño, Ricardo Ruíz‐Villaverde, et al.
JEADV Clinical Practice (2024)
Open Access | Times Cited: 2
Overlapping network meta‐analyses on psoriasis systemic treatments, an overview: quantity does not make quality
Robin Guelimi, Sivem Afach, Jean-Philippe Régnaux, et al.
British Journal of Dermatology (2021) Vol. 187, Iss. 1, pp. 29-41
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top